Mirae Asset Global ETFs Holdings
ACRV icon

Mirae Asset Global ETFs Holdings’s Acrivon Therapeutics ACRV Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,087
Closed -$14.4K – 3001
2025
Q1 		$14.4K Buy
7,087
+312
+5% +$1.68K ﹤0.01% 3006
2024
Q4 		$40.8K Buy
6,775
+304
+5% +$2.21K ﹤0.01% 2936
2024
Q3 		$45.3K Sell
6,471
-37
-0.6% -$292 ﹤0.01% 2932
2024
Q2 		$37.7K Buy
+6,508
New +$52.4K ﹤0.01% 2846

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's ACRV Position: Q2 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 7,087 shares — an estimated $14.4K sold.

Mirae Asset Global ETFs Holdings first reported a position in ACRV in Q2 2024 and held it in 4 quarters. The position peaked at $45.3K in Q3 2024. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 7,087 Acrivon Therapeutics shares in Q2 2025, an estimated $14.4K.
  • Mirae Asset Global ETFs Holdings first reported a position in Acrivon Therapeutics in Q2 2024 and held it in 4 quarters.
  • Mirae Asset Global ETFs Holdings's Acrivon Therapeutics position peaked at $45.3K in Q3 2024.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.